Observation for each participant will last for about 2 years in total. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Oral NAH therapy will be given per the standard approved dose once daily until the disease has progressed. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Participants in this study will receive either Radium-223 dichloride or a NAH therapy. Both of them are standard approved medications which are used in the treatment of advanced prostate cancer. The NAH drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy. Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Why Should I Register and Submit Results?.Trametinib 0.5 mg and 2 mg tablets andįor inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.Somatropin 5.83 mg/mL and 8 mg/mL solution for injection.Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection.Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens.Ruxolitinib 5 mg, 15 mg and 20 mg tablets.Pemetrexed 100 mg and 500 mg injections.Pembrolizumab 100 mg/4 mL solution for infusion.Pegylated liposomal doxorubicin 20 mg concentrate for infusion.Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets.Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension.Oxaliplatin 200 mg/40 mL concentrate for infusion.Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion.Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion.Nilotinib 50 mg, 150 mg and 200 mg capsules.Leuprorelin acetate 3.75 mg and 11.25 mg depot injections.Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules.Ipilimumab 50 mg/10 mL concentrate for solution for infusion.Goserelin 3.6 mg and 10.8 mg depot injections.Fulvestrant 250 mg/5 mL solution for injection.Eribulin mesylate 1 mg/2 mL solution for injection.Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion.Dasatinib 20 mg, 50 mg and 70 mg tablets.Cisplatin 100 mg/100 mL concentrate for infusion. Cetuximab 100 mg/20 mL solution for infusion.Cabozantinib 20 mg, 40 mg and 60 mg tablets.Brigatinib 30 mg, 90 mg and 180 mg tablets.Brentuximab vedotin 50 mg powder for concentrate for solution for infusion.Bendamustine 25 mg and 100 mg concentrate for infusion.Avelumab 200 mg/10 mL concentrate for solution for infusion.Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion.Afatinib 20 mg, 30 mg and 40 mg tablets.Abemaciclib 50 mg, 100 mg and 150 mg tablets.Based on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended:
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |